TScan Therapeutics, Inc. — Director's Dealing 2021

Jul 16, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: TScan Therapeutics, Inc. (TCRX)
CIK: 0001783328
Period of Report: 2021-07-15

Reporting Person: Westphal Christoph H (Director, 10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Voting Common Stock	914634	Direct
Voting Common Stock	121951	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Voting Common Stock (641848)		Indirect
Series B Preferred Stock	$		Voting Common Stock (332594)		Indirect
Series C Preferred Stock	$		Voting Common Stock (171063)		Indirect

Footnotes

F1: These shares are held by the Reporting Person's spouse.

F2: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock is convertible into shares of the Issuer's Voting Common Stock on a 1 for 1 basis at the holder's election and will automatically convert immediately prior to the closing of the Issuer's initial public offering. These shares have no expiration date.

F3: These shares are held by Longwood Fund IV, L.P. ("Longwood"). The general partner of Longwood is Longwood Fund IV GP, LLC ("Longwood GP"). Longwood GP may be deemed to have sole voting and dispositive power over the shares held by Longwood. Each of Richard Aldrich and Christoph Westphal, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood GP and may be deemed to share voting and dispositive power over of the shares held by Longwood. Each of Longwood GP and the Managers disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.